

# Binod Dhakal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4491788/publications.pdf>

Version: 2024-02-01

122  
papers

1,688  
citations

361413

20  
h-index

361022

35  
g-index

167  
all docs

167  
docs citations

167  
times ranked

2546  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. <i>JAMA Oncology</i> , 2018, 4, 343.	7.1	130
2	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2901-2912.	1.6	124
3	IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2017, 152, 478-485.	0.8	113
4	Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. <i>Blood</i> , 2021, 138, 1278-1281.	1.4	101
5	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2019, 134, 860-860.	1.4	80
6	Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. <i>Lancet Haematology</i> , 2018, 5, e220-e231.	4.6	76
7	Marizomib for central nervous system multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 221-225.	2.5	49
8	Peripheral Blood Grafts for T Cell Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1664-1670.	2.0	36
9	Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. <i>Cancer Cell</i> , 2022, 40, 340-342.	16.8	35
10	Novel biomarkers in multiple myeloma. <i>Translational Research</i> , 2018, 201, 49-59.	5.0	31
11	Multiple myeloma and COVID-19. <i>Leukemia</i> , 2020, 34, 1961-1963.	7.2	29
12	Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2466-2470.	5.2	29
13	Morbidities of lung cancer surgery in obese patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 379-384.	0.8	28
14	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. <i>BMC Cancer</i> , 2018, 18, 593.	2.6	28
15	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
16	The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. <i>Blood Reviews</i> , 2020, 41, 100643.	5.7	26
17	Incidence and survival of therapy related myeloid neoplasm in United States. <i>Leukemia Research</i> , 2018, 71, 95-99.	0.8	24
18	Plerixafor and Abbreviated-Course Granulocyte Colony-Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1926-1931.	2.0	23

#	ARTICLE	IF	CITATIONS
19	Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 10-14.	0.9	23
20	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1492-1497.	2.0	23
21	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 827-833.	2.0	23
22	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. <i>Bone Marrow Transplantation</i> , 2021, 56, 9-19.	2.4	22
23	Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, 34.	6.2	22
24	Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 921-931.	2.0	21
25	A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies. <i>Chest</i> , 2017, 152, e77-e80.	0.8	20
26	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
27	Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. <i>Case Reports in Hematology</i> , 2016, 2016, 1-4.	0.4	17
28	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 379-386.	0.4	17
29	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 165-172.	0.4	17
30	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 33-38.	1.1	17
31	Salvage second transplantation in relapsed multiple myeloma. <i>Leukemia</i> , 2021, 35, 1214-1217.	7.2	17
32	Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 225-231.	2.4	17
33	A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. <i>Cells</i> , 2021, 10, 1961.	4.1	16
34	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 56.	6.2	15
35	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	4.1	15
36	Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1285-1292.	1.0	14

#	ARTICLE	IF	CITATIONS
37	Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data. <i>Blood</i> , 2020, 136, 35-36.	1.4	14
38	Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2558-2562.	1.3	13
39	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 893-901.	2.0	13
40	Recent advances in understanding multiple myeloma. <i>F1000Research</i> , 2016, 5, 2053.	1.6	13
41	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. <i>JAMA Network Open</i> , 2019, 2, e196476.	5.9	12
42	Risk, Outcomes, and Predictors of Clostridium difficile Infection in Lymphoma: A Nationwide Study. <i>Southern Medical Journal</i> , 2018, 111, 628-633.	0.7	12
43	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2011-2017.	2.0	11
44	Use of IV Immunoglobulin G in Heparin-Induced Thrombocytopenia Patients Is Not Associated With Increased Rates of Thrombosis. <i>Chest</i> , 2020, 158, 1172-1175.	0.8	11
45	Autonomic nervous system control of multiple myeloma. <i>Blood Reviews</i> , 2021, 46, 100741.	5.7	11
46	A Novel PF4-Dependent P-Selectin Expression Assay (PEA) Facilitates Early Detection of Pathogenic HIT Antibodies: Implications for Diagnosis and Treatment of HIT. <i>Blood</i> , 2016, 128, 2599-2599.	1.4	11
47	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	1.2	11
48	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1288-1297.	2.0	10
49	Immunotherapy in Multiple Myeloma—Time for a Second Major Paradigm Shift. <i>JCO Oncology Practice</i> , 2021, 17, 405-413.	2.9	10
50	Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5). <i>Blood</i> , 2021, 138, 1835-1835.	1.4	10
51	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. <i>British Journal of Haematology</i> , 2022, 197, 28-40.	2.5	9
52	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 83.e1-83.e9.	1.2	9
53	Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 210-221.	3.8	8
54	Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1610-1614.	2.0	8

#	ARTICLE	IF	CITATIONS
55	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	2.5	8
56	Pemetrexed Induced Pneumonitis. <i>Clinics and Practice</i> , 2011, 1, e106.	1.4	8
57	Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. <i>Frontiers in Oncology</i> , 2022, 12, 786451.	2.8	8
58	Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1773-1780.	2.0	7
59	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1210-1213.	2.4	7
60	Metabolically Reprogrammed Polyclonal Autologous Rapa-201 Cell Therapy Yields a Promising Safety and Efficacy Profile in Relapsed and Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2021, 138, 2838-2838.	1.4	7
61	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 305-311.e2.	0.4	6
62	Myeloma sleeper agent in myeloid disguise. <i>Blood</i> , 2019, 134, 3-4.	1.4	6
63	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 2791-2801.	4.1	6
64	Marizomib for CNS-Multiple Myeloma. <i>Blood</i> , 2016, 128, 2118-2118.	1.4	6
65	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial. <i>Blood</i> , 2021, 138, 481-481.	1.4	5
66	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3991-3995.	5.2	5
67	Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. <i>American Journal of Hematology</i> , 2017, 92, E563-E565.	4.1	4
68	When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e251-e258.	0.4	4
69	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2229-2236.	2.0	4
70	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
71	Trends in the use of therapeutic plasma exchange in multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2020, 35, 307-315.	1.3	4
72	Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e468-e473.	0.4	4

#	ARTICLE	IF	CITATIONS
73	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
74	Localized Lymph Node Light Chain Amyloidosis. <i>Case Reports in Hematology</i> , 2015, 2015, 1-4.	0.4	3
75	Developing a Case-Based Blended Learning Ecosystem to Optimize Precision Medicine: Reducing Overdiagnosis and Overtreatment. <i>Healthcare (Switzerland)</i> , 2018, 6, 78.	2.0	3
76	Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma—Reply. <i>JAMA Oncology</i> , 2018, 4, 1618.	7.1	3
77	An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. <i>Journal of Clinical Apheresis</i> , 2019, 34, 686-691.	1.3	3
78	Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1626-1626.	1.4	3
79	Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 502-510.	4.1	3
80	Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	3
81	Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. <i>American Journal of Hematology</i> , 2022, 97, 1170-1177.	4.1	3
82	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 210-215.	3.0	2
83	Impact of Autologous Hematopoietic Stem Cell Transplant (AHCT) on Measurable Residual Disease (MRD) By Next Generation Sequencing (NGS) in the Setting of Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Quadruplet Induction.. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S24.	2.0	2
84	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. <i>EJHaem</i> , 2021, 2, 375-384.	1.0	2
85	Laboratory Mice — A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 667054.	4.8	2
86	Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM). <i>Blood</i> , 2019, 134, 783-783.	1.4	2
87	Early Mortality in Patients with Acute Promyelocytic Leukemia (APL) Treated in Teaching Versus Non-Teaching Hospitals. <i>Blood</i> , 2016, 128, 2784-2784.	1.4	2
88	Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8030-8030.	1.6	2
89	Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy. <i>Blood</i> , 2021, 138, 483-483.	1.4	2
90	Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e495-e497.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.. Journal of Clinical Oncology, 2021, 39, 8029-8029.	1.6	1
92	Intravenous Immunoglobulin (IVIg) Is a Highly Effective Treatment for HIT: Critical Role of the IgG Fc Domain in Inhibiting HIT Antibody-Mediated Platelet Activation. Blood, 2016, 128, 2600-2600.	1.4	1
93	Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age. Blood, 2016, 128, 3456-3456.	1.4	1
94	Incidence and Overall Survival of Therapy Related Myeloid Neoplasm in United States. Blood, 2016, 128, 3992-3992.	1.4	1
95	eICU STUDY. International Journal of User-Driven Healthcare, 2014, 4, 1-5.	0.1	1
96	Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation. Blood, 2019, 134, 266-266.	1.4	1
97	The significance of beta-II microglobulin ( $\beta_2M$ ) and International Staging System (ISS) in multiple myeloma (MM) patients (pts.) with renal impairment (RI).. Journal of Clinical Oncology, 2020, 38, 8544-8544.	1.6	1
98	Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 229-233.	1.3	0
99	Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e775-e781.	0.4	0
100	Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. Leukemia Research, 2021, 109, 106648.	0.8	0
101	How safe is surgery in obese lung cancer patients?. Journal of Clinical Oncology, 2012, 30, e17555-e17555.	1.6	0
102	Plerixafor plus G-CSF (P+G) compared with G-CSF alone (G) for hematopoietic progenitor cell (HPC) mobilization in AL amyloidosis (AL).. Journal of Clinical Oncology, 2014, 32, 8606-8606.	1.6	0
103	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. Blood, 2015, 126, 2711-2711.	1.4	0
104	"Tailoring" Hematopoietic Progenitor Cell Collection: Impact of a Data-Driven Prediction Algorithm for Blood Volume Processing in Large Volume Leukapheresis. Blood, 2016, 128, 2188-2188.	1.4	0
105	Use of "Big Data" to Define Disease Burden, Complication Rates and Healthcare Costs in Patients with Heparin Induced Thrombocytopenia (HIT). Blood, 2016, 128, 418-418.	1.4	0
106	Pilot Study of Prognostic Impact of Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Plasma Levels of CXC-Chemokines (CXCL-4 and CXCL-7) in Patients with Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 4678-4678.	1.4	0
107	Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials.. Journal of Clinical Oncology, 2017, 35, 8022-8022.	1.6	0
108	Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.. Journal of Clinical Oncology, 2017, 35, 8012-8012.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Trends in utilization and in-hospital outcomes of high dose therapy and autologous stem cell transplantation among patients with AL amyloidosis in the United States.. Journal of Clinical Oncology, 2018, 36, e20000-e20000.	1.6	0
110	Evaluation and identification of protocols for safe and efficacious institutional administration of intravenous immune globulin in hypogammaglobulinemia associated with chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 250-250.	1.6	0
111	Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Tj ETQq1 1 0.784314 rgBT /Oyerlock 10	1.4	0
112	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. Blood, 2018, 132, 3544-3544.	1.4	0
113	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. Blood, 2018, 132, 617-617.	1.4	0
114	Use of Intravenous Immunoglobulin G in HIT: Impact on Thrombosis and Mortality in a Population-Based Study. Blood, 2018, 132, 2512-2512.	1.4	0
115	Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2018, 132, 1998-1998.	1.4	0
116	Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood, 2019, 134, 2188-2188.	1.4	0
117	Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT). Blood, 2019, 134, 3088-3088.	1.4	0
118	Exploring multiple myeloma survivor interest in lifestyle interventions.. Journal of Clinical Oncology, 2020, 38, e20558-e20558.	1.6	0
119	Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. Blood, 2021, 138, 4091-4091.	1.4	0
120	Budesonide Prophylaxis Reduces Engraftment Syndrome (ES) after Autologous Hematopoietic Cell Transplantation (autoHCT) in Multiple Myeloma (MM). Blood, 2020, 136, 35-36.	1.4	0
121	Rap1A, Rap1B, and $\beta$ -Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.. Yale Journal of Biology and Medicine, 2022, 95, 45-56.	0.2	0
122	Kinetics of humoral immunodeficiency with bispecific antibody therapy in multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8049-8049.	1.6	0